The estimated Net Worth of Steven M Rauscher is at least $6.6 Тысяча dollars as of 15 May 2018. Steven Rauscher owns over 10,000 units of Acorda Therapeutics Inc stock worth over $6,600 and over the last 19 years Steven sold ACOR stock worth over $0.
Steven has made over 6 trades of the Acorda Therapeutics Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently Steven exercised 10,000 units of ACOR stock worth $201,600 on 15 May 2018.
The largest trade Steven's ever made was exercising 30,000 units of Acorda Therapeutics Inc stock on 5 August 2010 worth over $244,200. On average, Steven trades about 2,613 units every 135 days since 2005. As of 15 May 2018 Steven still owns at least 10,000 units of Acorda Therapeutics Inc stock.
You can see the complete history of Steven Rauscher stock trades at the bottom of the page.
Over the last 19 years, insiders at Acorda Therapeutics Inc have traded over $155,173,492 worth of Acorda Therapeutics Inc stock and bought 1,139,691 units worth $17,085,546 . The most active insiders traders include Capital Management Lp Scopi..., Ian F Smith и Ron Cohen. On average, Acorda Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $19,752. The most recent stock trade was executed by Ron Cohen on 16 March 2023, trading 20,156 units of ACOR stock currently worth $12,497.
acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate
Acorda Therapeutics Inc executives and other stock owners filed with the SEC include: